BCL6 and breast cancer: In the present study, we found that FLLL31 activates the mitochondria‐dependent apoptosis pathway by targeting the FOXO4/BCL6 axis to inhibit the malignant phenotype of BC cells, which provides a new drug candidate and target for the treatment of BC.